Inspiratory Muscle Training and Behavioral Support to Alleviate Dyspnea and Promote Walking in Lung Cancer Survivors: A Pilot Study

Sponsor
Kaiser Permanente (Other)
Overall Status
Recruiting
CT.gov ID
NCT05059132
Collaborator
American Lung Association (Other)
40
1
2
17.6
2.3

Study Details

Study Description

Brief Summary

This is a pilot randomized study to investigate the feasibility, acceptability, safety, and effects of a novel tele-rehabilitation intervention for stage I-IIIA lung cancer survivors following curative intent therapy.

The specific aims and hypotheses are:

Specific Aim 1: Conduct a pilot, phase IIb, parallel randomized (1:1) study to investigate the feasibility, acceptability, and safety of inspiratory muscle training and behavioral support to promote walking in tele-rehabilitation with stage I-IIIA lung cancer survivors following curative intent therapy (N=40).

Hypothesis 1a: ≥ 20% eligible patients will enroll; ≥75% of participants will achieve ≥75% adherence to the tele-rehabilitation program.

Hypothesis 1b: ≥75% of participants will perceive tele-rehabilitation as acceptable (Telemedicine Satisfaction and Usefulness Questionnaire ≥4). There will be 0 intervention adverse events.

Specific Aim 2: Explore the effects of the tele-rehabilitation program (N=40).

Hypothesis 2: At 12 weeks, participants in the tele-rehabilitation (experimental) arm, compared to education only (control) arm, will have a trend of greater improvements in outcomes, including:

  1. accelerometry-measured physical activity (primary outcome); and

  2. functional capacity, self-reported physical activity, control of dyspnea and anxiety symptoms, sleep quality, and quality of life (secondary outcomes).

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Tele-rehabilitation
  • Other: Education only
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a pilot, parallel randomized study of an exercise + behavioral support intervention to reduce dyspnea and improve walking behavior among lung cancer survivors following curative intent therapy. Forty participants will be randomized 1:1 to the intervention or control arm, with assessments of feasibility, acceptability, safety, and patient-centered outcomes. The intervention period is 12 weeks.This is a pilot, parallel randomized study of an exercise + behavioral support intervention to reduce dyspnea and improve walking behavior among lung cancer survivors following curative intent therapy. Forty participants will be randomized 1:1 to the intervention or control arm, with assessments of feasibility, acceptability, safety, and patient-centered outcomes. The intervention period is 12 weeks.
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Tele-rehabilitation Following Curative Intent Therapy of Lung Cancer
Actual Study Start Date :
Jan 10, 2022
Anticipated Primary Completion Date :
Mar 31, 2023
Anticipated Study Completion Date :
Jun 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tele-rehabilitation

Participants in the tele-rehabilitation arm will receive a home-based, remotely delivered rehabilitation program.

Behavioral: Tele-rehabilitation
The tele-rehabilitation intervention will include education, inspiratory muscle training, and behavioral support to promote walking.

Active Comparator: Education only

Participants in the education arm will receive educational materials only, delivered through telecommunication messages.

Other: Education only
The education only arm will receive information on the importance of general exercise following lung cancer treatment.

Outcome Measures

Primary Outcome Measures

  1. Difference in change in accelerometry-measured physical activity between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12).]

    Physical activity will be measured by the activPAL4 device (PAL Technologies, Ltd).

Secondary Outcome Measures

  1. Difference in change in functional capacity between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Functional capacity will be measured using the mobile six-minute walk test.

  2. Difference in change in self-reported physical activity between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Self-reported physical activity will be measured using the International Physical Activity Questionnaire - Short Form

  3. Difference in change in control of dyspnea between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Dyspnea control will be measured using the the University of California, San Diego Shortness of Breath Questionnaire.

  4. Difference in change in anxiety symptoms between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Anxiety symptoms will be measured using the General Anxiety Disorder-7

  5. Difference in change in sleep quality between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Sleep quality will be measured using the Pittsburgh Sleep Quality Index

  6. Difference in change in quality of life between baseline and week 12 [Baseline, mid study (week 6), and end of study (week 12)]

    Quality of life will be measured using the St. George's Respiratory Questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • history of stage I-IIIA lung cancer;

  • completed curative intent therapy (i.e., lung cancer resection surgery, definitive radiation, or concurrent chemoradiation) within 1-6 months;

  • access to a mobile phone or personal computer with internet access;

  • willingness to wear activity trackers

Exclusion Criteria:
  • dementia (or cognitive impairment identified by chart review) resulting in inability to follow directions or provide written informed consent;

  • acute myocardial infarction, ventricular tachycardia, ventricular fibrillation, acute cerebrovascular event, or acute asthma exacerbation in past 2 months;

  • spontaneous pneumothorax in past 12 months;

  • Parkinson's disease;

  • multiple sclerosis;

  • amyotrophic lateral sclerosis;

  • additional movement/gait disorders that may be identified by chart review

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kaiser Permanente Colorado Aurora Colorado United States 80014

Sponsors and Collaborators

  • Kaiser Permanente
  • American Lung Association

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kaiser Permanente
ClinicalTrials.gov Identifier:
NCT05059132
Other Study ID Numbers:
  • LCD-820773
First Posted:
Sep 28, 2021
Last Update Posted:
Feb 1, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kaiser Permanente
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 1, 2022